quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:06:17·1148d
NEWSRelease
Apexigen Inc. logo
Avenue Therapeutics Inc. logo
Biophytis SA logo
+9

12 Health Care Stocks Moving In Thursday's Pre-Market Session

APGN· Apexigen Inc.ATXI· Avenue Therapeutics Inc.BPTS· Biophytis SABRTX· BioRestorative Therapies Inc.CANO· Cano Health Inc.CELU· Celularity Inc.
Health Care
Original source

Companies

  • APGN
    Apexigen Inc.
    Health Care
  • ATXI
    Avenue Therapeutics Inc.
    Health Care
  • BPTS
    Biophytis SA
    Health Care
  • BRTX
    BioRestorative Therapies Inc.
    Health Care
  • CANO
    Cano Health Inc.
    Health Care
  • CELU
    Celularity Inc.
    Health Care
  • CMRX
    Chimerix Inc.
    Health Care
  • GNLX
    Genelux Corporation
    Health Care
  • LHDX
    Lucira Health Inc.
    Health Care
  • ONCS
    OncoSec Medical Incorporated
    Health Care
  • OTRK
    Ontrak Inc.
    Health Care
  • XBIO
    Xenetic Biosciences Inc.
    Health Care

Recent analyst ratings

  • Oct 21GNLXUpdateLake Street$16.00
  • Oct 29GNLXUpdateGuggenheim$8.00
  • Aug 28GNLXUpdateROTH MKM$10.00
  • Dec 5OTRKUpdateROTH MKM$4.00
  • Nov 27GNLXUpdateH.C. Wainwright$35.00
  • Sep 12GNLXUpdateMaxim Group$40.00

Related

  • SEC8h
    BioRestorative Therapies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
  • INSIDER9h
    Interim CEO and CFO Parslow James F was granted 100,000 shares (SEC Form 4)
  • SEC1d
    Amendment: SEC Form SCHEDULE 13D/A filed by Celularity Inc.
  • NEWS1d
    Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
  • SEC2d
    Celularity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Material Modification to Rights of Security Holders, Leadership Update, Other Events, Financial Statements and Exhibits
  • PR2d
    NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment
  • PR2d
    Celularity Announces Closing of Transaction with NexGel
  • PR2d
    BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022